Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley, Jonathan Baber, Martijn P Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk, Paul Roepman, Mircea Voda, Haiko J Bloemendal, Vivianne C G Tjan-Heijnen, Carla M L van Herpen, Mariette Labots, Petronella O Witteveen, Egbert F Smit, Stefan Sleijfer, Emile E Voest, Edwin Cuppen, Peter Priestley, Jonathan Baber, Martijn P Lolkema, Neeltje Steeghs, Ewart de Bruijn, Charles Shale, Korneel Duyvesteyn, Susan Haidari, Arne van Hoeck, Wendy Onstenk, Paul Roepman, Mircea Voda, Haiko J Bloemendal, Vivianne C G Tjan-Heijnen, Carla M L van Herpen, Mariette Labots, Petronella O Witteveen, Egbert F Smit, Stefan Sleijfer, Emile E Voest, Edwin Cuppen
Abstract
Metastatic cancer is a major cause of death and is associated with poor treatment efficacy. A better understanding of the characteristics of late-stage cancer is required to help adapt personalized treatments, reduce overtreatment and improve outcomes. Here we describe the largest, to our knowledge, pan-cancer study of metastatic solid tumour genomes, including whole-genome sequencing data for 2,520 pairs of tumour and normal tissue, analysed at median depths of 106× and 38×, respectively, and surveying more than 70 million somatic variants. The characteristic mutations of metastatic lesions varied widely, with mutations that reflect those of the primary tumour types, and with high rates of whole-genome duplication events (56%). Individual metastatic lesions were relatively homogeneous, with the vast majority (96%) of driver mutations being clonal and up to 80% of tumour-suppressor genes being inactivated bi-allelically by different mutational mechanisms. Although metastatic tumour genomes showed similar mutational landscape and driver genes to primary tumours, we find characteristics that could contribute to responsiveness to therapy or resistance in individual patients. We implement an approach for the review of clinically relevant associations and their potential for actionability. For 62% of patients, we identify genetic variants that may be used to stratify patients towards therapies that either have been approved or are in clinical trials. This demonstrates the importance of comprehensive genomic tumour profiling for precision medicine in cancer.
Conflict of interest statement
E.E.V. is a supervisory board member of the Hartwig Medical Foundation.
Figures
References
- The Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 2013;45:1113–1120.
- The International Cancer Genome Consortium International network of cancer genome projects. Nature. 2010;464:993–998.
- Gröbner SN, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321–327.
- Ma X, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature. 2018;555:371–376.
- Hyman DM, Taylor BS, Baselga J. Implementing genome-driven oncology. Cell. 2017;168:584–599.
- Yates LR, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169–184.e7.
- Naxerova K, et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science. 2017;357:55–60.
- Gundem G, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520:353–357.
- Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017;23:703–713.
- Robinson DR, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548:297–303.
- Klein CA. Selection and adaptation during metastatic cancer progression. Nature. 2013;501:365–372.
- McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613–628.
- Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
- Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O. & Stein, L. D. Pan-cancer analysis of whole genomes. Preprint at (2017).
- Kucab JE, et al. A compendium of mutational signatures of environmental agents. Cell. 2019;177:821–836.e16.
- Gryfe R, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 2000;342:69–77.
- Wedge DC, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat. Genet. 2018;50:682–692.
- Cai Y, et al. Loss of chromosome 8p governs tumor progression and drug response by altering lipid metabolism. Cancer Cell. 2016;29:751–766.
- Sato Y, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 2013;45:860–867.
- Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477.
- Zack TI, et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 2013;45:1134–1140.
- Carter SL, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 2012;30:413–421.
- Bielski CM, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 2018;50:1189–1195.
- Martincorena I, et al. Universal patterns of selection in cancer and somatic tissues. Cell. 2017;171:1029–1041.e21.
- Marusiak AA, et al. Recurrent MLK4 loss-of-function mutations suppress JNK signaling to promote colon tumorigenesis. Cancer Res. 2016;76:724–735.
- Forbes SA, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45(D1):D777–D783.
- Glover TW, Wilson TE, Arlt MF. Fragile sites in cancer: more than meets the eye. Nat. Rev. Cancer. 2017;17:489–501.
- Mehta GA, et al. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Res. Treat. 2017;162:439–450.
- Pinnell N, et al. The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T cell development and leukemia. Immunity. 2015;43:870–883.
- Salari K, et al. CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Proc. Natl Acad. Sci. USA. 2012;109:E3196–E3205.
- Futreal PA, et al. A census of human cancer genes. Nat. Rev. Cancer. 2004;4:177–183.
- Sabarinathan, R. et al. The whole-genome panorama of cancer drivers. Preprint at (2017).
- Cuykendall TN, Rubin MA, Khurana E. Non-coding genetic variation in cancer. Current Opinion in Systems Biology. 2017;1:9–15.
- Friedl W, et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut. 2001;48:515–521.
- Bailey MH, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371–385.e18.
- Cives M, Simone V, Rizzo FM, Silvestris F. NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget. 2016;7:57414–57429.
- Viswanathan SR, et al. Structural alterations driving castration-resistant prostate cancer revealed by linked-read genome sequencing. Cell. 2018;174:433–447.e19.
- The Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489:519–525.
- Griffith M, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat. Genet. 2017;49:170–174.
- Chakravarty, D. et al. OncoKB: a precision oncology knowledge base. JCO Precis. Oncol. 10.1200/PO.17.00011 (2017).
- Tamborero D, et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Med. 2018;10:25.
- Yang YA, Yu J. Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer. Genes Dis. 2015;2:144–151.
- Knudson AG., Jr Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA. 1971;68:820–823.
- Andor N, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 2016;22:105–113.
- Reiter JG, et al. Minimal functional driver gene heterogeneity among untreated metastases. Science. 2018;361:1033–1037.
- van der Velden DL, et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127–131.
- Hellmann MD, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 2018;378:2093–2104.
- Carbone DP, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 2017;376:2415–2426.
- Zhang J, et al. The International Cancer Genome Consortium Data Portal. Nat. Biotechnol. 2019;37:367–369.
- van Dessel, L. F. et al. The genomic landscape of metastatic castration-resistant prostate cancers using whole genome sequencing reveals multiple distinct genotypes with potential clinical impact. Preprint at (2019).
- Angus, L. et al. Genomic landscape of metastatic breast cancer and its clinical implications. Nat. Genet.51, 1450–1458 (2019).
- Bins S, et al. Implementation of a multicenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies. Oncologist. 2017;22:33–40.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009;25:1754–1760.
- McKenna A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303.
- Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at (2018).
- Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics. 2013;43:11.10.1–11.10.33.
- Saunders CT, et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics. 2012;28:1811–1817.
- Chen X, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220–1222.
- Van Loo P, et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA. 2010;107:16910–16915.
- Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 2018;10:33.
- Huang K-L, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173:355–370.e14.
- Kalia SS, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 2017;19:249–255.
- Huang MN, et al. MSIseq: software for assessing microsatellite instability from catalogs of somatic mutations. Sci. Rep. 2015;5:13321.
- Zerbino DR, et al. Ensembl 2018. Nucleic Acids Res. 2018;46(D1):D754–D761.
- Mermel CH, et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41.
- Mateo J, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) Ann. Oncol. 2018;29:1895–1902.
- Kibbe WA, et al. Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data. Nucleic Acids Res. 2015;43:D1071–D1078.
- Black J, et al. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu Expression. Mol. Cancer Ther. 2016;15:1900–1909.
- Bond CE, et al. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis. Oncotarget. 2016;7:70589–70600.
- Fleming NI, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73:725–735.
Source: PubMed